| Variable . | . |
|---|---|
| Age (years), median (IQR) | 51 (43–57) |
| Female, n (%) | 69 (31.2) |
| Risk factor for HIV infection, n (%) | |
| heterosexual | 97 (43.9) |
| MSM | 97 (43.9) |
| IVDU | 23 (10.4) |
| other | 4 (1.8) |
| Positive for anti-HCV antibodies, n (%) | 29 (13.1) |
| Time from HIV diagnosis (years), median (IQR) | 14 (7–20) |
| CDC stage C, n (%) | 65 (29.4) |
| Time on ART (years), median (IQR) | 11 (5–17) |
| Nadir CD4+ (cells/μL), median (IQR) | 209 (70–304) |
| Zenith HIV-RNA (log copies/mL), median (IQR) | 4.78 (4.14–5.36) |
| Zenith HIV-RNA >500 000 copies/mL, n (%) | 16 (7.2) |
| Previous virological failure, n (%) | 96 (43.4) |
| CD4+ count (cells/μL), median (IQR) | 640 (510–865) |
| Time of virological suppression (months), median (IQR) | 96 (44–140) |
| Presence of M184V resistance mutation, n (%) | 20 (9.0) |
| Previous HAART regimen, n (%) | |
| 2 NRTIs + NNRTI | 42 (19.0) |
| 2 NRTIs + PI or boosted PI | 18 (8.1) |
| 2 NRTIs + integrase inhibitor | 43 (19.5) |
| dual therapy | 115 (52.0) |
| other | 3 (1.4) |
| Reasons for switch, n (%) | |
| simplification | 72 (32.6) |
| dyslipidaemia | 60 (27.1) |
| gastrointestinal or liver toxicity | 22 (10.0) |
| renal toxicity | 16 (7.2) |
| osteoporosis | 12 (5.4) |
| neurological toxicity | 5 (2.3) |
| other toxicities | 19 (8.6) |
| drug–drug interactions | 8 (3.6) |
| other | 7 (3.2) |
| Variable . | . |
|---|---|
| Age (years), median (IQR) | 51 (43–57) |
| Female, n (%) | 69 (31.2) |
| Risk factor for HIV infection, n (%) | |
| heterosexual | 97 (43.9) |
| MSM | 97 (43.9) |
| IVDU | 23 (10.4) |
| other | 4 (1.8) |
| Positive for anti-HCV antibodies, n (%) | 29 (13.1) |
| Time from HIV diagnosis (years), median (IQR) | 14 (7–20) |
| CDC stage C, n (%) | 65 (29.4) |
| Time on ART (years), median (IQR) | 11 (5–17) |
| Nadir CD4+ (cells/μL), median (IQR) | 209 (70–304) |
| Zenith HIV-RNA (log copies/mL), median (IQR) | 4.78 (4.14–5.36) |
| Zenith HIV-RNA >500 000 copies/mL, n (%) | 16 (7.2) |
| Previous virological failure, n (%) | 96 (43.4) |
| CD4+ count (cells/μL), median (IQR) | 640 (510–865) |
| Time of virological suppression (months), median (IQR) | 96 (44–140) |
| Presence of M184V resistance mutation, n (%) | 20 (9.0) |
| Previous HAART regimen, n (%) | |
| 2 NRTIs + NNRTI | 42 (19.0) |
| 2 NRTIs + PI or boosted PI | 18 (8.1) |
| 2 NRTIs + integrase inhibitor | 43 (19.5) |
| dual therapy | 115 (52.0) |
| other | 3 (1.4) |
| Reasons for switch, n (%) | |
| simplification | 72 (32.6) |
| dyslipidaemia | 60 (27.1) |
| gastrointestinal or liver toxicity | 22 (10.0) |
| renal toxicity | 16 (7.2) |
| osteoporosis | 12 (5.4) |
| neurological toxicity | 5 (2.3) |
| other toxicities | 19 (8.6) |
| drug–drug interactions | 8 (3.6) |
| other | 7 (3.2) |
| Variable . | . |
|---|---|
| Age (years), median (IQR) | 51 (43–57) |
| Female, n (%) | 69 (31.2) |
| Risk factor for HIV infection, n (%) | |
| heterosexual | 97 (43.9) |
| MSM | 97 (43.9) |
| IVDU | 23 (10.4) |
| other | 4 (1.8) |
| Positive for anti-HCV antibodies, n (%) | 29 (13.1) |
| Time from HIV diagnosis (years), median (IQR) | 14 (7–20) |
| CDC stage C, n (%) | 65 (29.4) |
| Time on ART (years), median (IQR) | 11 (5–17) |
| Nadir CD4+ (cells/μL), median (IQR) | 209 (70–304) |
| Zenith HIV-RNA (log copies/mL), median (IQR) | 4.78 (4.14–5.36) |
| Zenith HIV-RNA >500 000 copies/mL, n (%) | 16 (7.2) |
| Previous virological failure, n (%) | 96 (43.4) |
| CD4+ count (cells/μL), median (IQR) | 640 (510–865) |
| Time of virological suppression (months), median (IQR) | 96 (44–140) |
| Presence of M184V resistance mutation, n (%) | 20 (9.0) |
| Previous HAART regimen, n (%) | |
| 2 NRTIs + NNRTI | 42 (19.0) |
| 2 NRTIs + PI or boosted PI | 18 (8.1) |
| 2 NRTIs + integrase inhibitor | 43 (19.5) |
| dual therapy | 115 (52.0) |
| other | 3 (1.4) |
| Reasons for switch, n (%) | |
| simplification | 72 (32.6) |
| dyslipidaemia | 60 (27.1) |
| gastrointestinal or liver toxicity | 22 (10.0) |
| renal toxicity | 16 (7.2) |
| osteoporosis | 12 (5.4) |
| neurological toxicity | 5 (2.3) |
| other toxicities | 19 (8.6) |
| drug–drug interactions | 8 (3.6) |
| other | 7 (3.2) |
| Variable . | . |
|---|---|
| Age (years), median (IQR) | 51 (43–57) |
| Female, n (%) | 69 (31.2) |
| Risk factor for HIV infection, n (%) | |
| heterosexual | 97 (43.9) |
| MSM | 97 (43.9) |
| IVDU | 23 (10.4) |
| other | 4 (1.8) |
| Positive for anti-HCV antibodies, n (%) | 29 (13.1) |
| Time from HIV diagnosis (years), median (IQR) | 14 (7–20) |
| CDC stage C, n (%) | 65 (29.4) |
| Time on ART (years), median (IQR) | 11 (5–17) |
| Nadir CD4+ (cells/μL), median (IQR) | 209 (70–304) |
| Zenith HIV-RNA (log copies/mL), median (IQR) | 4.78 (4.14–5.36) |
| Zenith HIV-RNA >500 000 copies/mL, n (%) | 16 (7.2) |
| Previous virological failure, n (%) | 96 (43.4) |
| CD4+ count (cells/μL), median (IQR) | 640 (510–865) |
| Time of virological suppression (months), median (IQR) | 96 (44–140) |
| Presence of M184V resistance mutation, n (%) | 20 (9.0) |
| Previous HAART regimen, n (%) | |
| 2 NRTIs + NNRTI | 42 (19.0) |
| 2 NRTIs + PI or boosted PI | 18 (8.1) |
| 2 NRTIs + integrase inhibitor | 43 (19.5) |
| dual therapy | 115 (52.0) |
| other | 3 (1.4) |
| Reasons for switch, n (%) | |
| simplification | 72 (32.6) |
| dyslipidaemia | 60 (27.1) |
| gastrointestinal or liver toxicity | 22 (10.0) |
| renal toxicity | 16 (7.2) |
| osteoporosis | 12 (5.4) |
| neurological toxicity | 5 (2.3) |
| other toxicities | 19 (8.6) |
| drug–drug interactions | 8 (3.6) |
| other | 7 (3.2) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
